Abstract
Sirolimus (rapamycin), a macrolide antibiotic approved for use as an immunosuppressive agent in the prevention of organ rejection, is a cell proliferation inhibitor and regulator of the immune response which acts through inhibition of TOR (target of rapamycin), a kinase essential to cell cycle progression. Recent studies suggest that the TOR pathway is critical to overall cell function, and at a basic mechanistic level, may be a regulator and potential therapeutic target involved in many of the major (and minor) disorders seen in man today. Cardiovascular diseases including restenosis following percutaneous coronary intervention as well as the more widespread condition of atherosclerosis, share this common involvement of TOR. The present report addresses the current state of intervention in cardiovascular disorders with Sirolimus and similar inhibitors of TOR, including the rationale for this approach and the successes observed to date. Success of the first drug-eluting stent to locally treat restenosis in the clinic is discussed, as are preclinical studies addressing a role in overall atherosclerosis in animal models. In addition, due to the known toxicities when given systemically, an approach for targeted delivery to local areas of vascular disease is discussed.
Keywords: Drug-eluting stents, Sirolimus, Rapamycin derivatives, Paclitaxel, Eluting Stent Systems, Coronary artery, neointimal hyperplasia, restenosis, taxol, coronary artery disease, drug-eluting stent, clinical trials, bare metal stent, angioplasty, sirolimus-eluting stents, Chemotherapy, -tubulin, lipophilicity, Palmaz-Schatz stents, intraintimal hemorrhage, Antiplatelet therapy, clopidogrel, angiographic stenosis, myocardial infarction, Academic Research Consortium, thrombosis, Stenting of Saphenous Vein Grafts, vascular brachytherapy, brachytherapy, chronic total occlusions, SYNTAX trial, XIENCE V stent, femoropopliteal disease
Current Pharmaceutical Design
Title: Sirolimus and its Analogs and its Effects on Vascular Diseases
Volume: 16 Issue: 36
Author(s): Steven J. Adelman
Affiliation:
Keywords: Drug-eluting stents, Sirolimus, Rapamycin derivatives, Paclitaxel, Eluting Stent Systems, Coronary artery, neointimal hyperplasia, restenosis, taxol, coronary artery disease, drug-eluting stent, clinical trials, bare metal stent, angioplasty, sirolimus-eluting stents, Chemotherapy, -tubulin, lipophilicity, Palmaz-Schatz stents, intraintimal hemorrhage, Antiplatelet therapy, clopidogrel, angiographic stenosis, myocardial infarction, Academic Research Consortium, thrombosis, Stenting of Saphenous Vein Grafts, vascular brachytherapy, brachytherapy, chronic total occlusions, SYNTAX trial, XIENCE V stent, femoropopliteal disease
Abstract: Sirolimus (rapamycin), a macrolide antibiotic approved for use as an immunosuppressive agent in the prevention of organ rejection, is a cell proliferation inhibitor and regulator of the immune response which acts through inhibition of TOR (target of rapamycin), a kinase essential to cell cycle progression. Recent studies suggest that the TOR pathway is critical to overall cell function, and at a basic mechanistic level, may be a regulator and potential therapeutic target involved in many of the major (and minor) disorders seen in man today. Cardiovascular diseases including restenosis following percutaneous coronary intervention as well as the more widespread condition of atherosclerosis, share this common involvement of TOR. The present report addresses the current state of intervention in cardiovascular disorders with Sirolimus and similar inhibitors of TOR, including the rationale for this approach and the successes observed to date. Success of the first drug-eluting stent to locally treat restenosis in the clinic is discussed, as are preclinical studies addressing a role in overall atherosclerosis in animal models. In addition, due to the known toxicities when given systemically, an approach for targeted delivery to local areas of vascular disease is discussed.
Export Options
About this article
Cite this article as:
J. Adelman Steven, Sirolimus and its Analogs and its Effects on Vascular Diseases, Current Pharmaceutical Design 2010; 16 (36) . https://dx.doi.org/10.2174/138161210794454923
DOI https://dx.doi.org/10.2174/138161210794454923 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Healthy Gut for a Healthy Brain: Preclinical, Clinical and Regulatory Aspects
Current Neuropharmacology Towards a Better Understanding of Cardiac and Vascular Disease in Patients with Chronic Kidney Disease
Current Cardiology Reviews Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design Evaluating Oxidative Stress in Human Cardiovascular Disease: Methodological Aspects and Considerations
Current Medicinal Chemistry Nanomedicine Against Malaria
Current Medicinal Chemistry Cardiovascular Changes in Menopause
Current Cardiology Reviews Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Blocking Leukocyte Rolling: Does it have a Role in Disease Prevention?
Vascular Disease Prevention (Discontinued) Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Secondary Stroke Prevention in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Vascular Disease Prevention (Discontinued) Transient Receptor Potential (TRP) Cation Channels in Diabetes
Current Topics in Medicinal Chemistry New Insights into Redox-Modulated Cell Signaling
Current Pharmaceutical Design Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
Current Vascular Pharmacology Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Disturbed Homeostasis in Patients with Acute Psychosis
Current Psychiatry Reviews Aptamers: Selection, Modification and Application to Nervous System Diseases
Current Medicinal Chemistry Molecular Mechanisms Regulating Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Association of Mean Platelet Volume with Hypertension in Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Cardiovascular Complications in Diabetes: Lessons from Animal Models
Current Medicinal Chemistry